Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Chu, Jin ^a   Praticò, Domenico ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 lipoxygenase activating protein; Alzheimer's disease; Amyloid beta precursor protein; Amyloid ; Animal model

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; BETA SECRETASE 1; CARRIER PROTEINS AND BINDING PROTEINS; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN A; DISINTEGRIN; GAMMA SECRETASE; METALLOPROTEINASE DOMAIN CONTAINING PROTEIN 10; NOTCH RECEPTOR; QUIFLAPON; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STEADY STATE;

EID: 84862239252     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-127     Document Type: Article

References (27)

1. Murphy RC, Gijon MA. Biosynthesis and metabolism of leukotrienes. Biochem J 2007, 405:379-395. 10.1042/BJ20070289, 17623009.
2. Mandal AK, Skoch J, Bacskai BJ, Hyman BT, Christmas P, Miller D, Yamin TT, Xu S, Wisniewski D, Evans JF, Soberman RJ. The membrane organization of leukotriene synthesis. Proc Natl Acad Sci USA 2004, 101:6587-6592. 10.1073/pnas.0308523101, 404089, 15084748.
3. Chinnici CM, Yao Y, Praticò D. The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Neurobiol Aging 2007, 28:1457-1462. 10.1016/j.neurobiolaging.2006.06.007, 16930777.
4. Ikonomovic MD, Abrahamson EE, Uz T, Manev H, Dekosky ST. Increased 5-lipooxygenase imunoreactivity in hippocampus of patients with Alzheimer' diseases. J Histochem Cytochem 2008, 56:1065-1073. 10.1369/jhc.2008.951855, 2583907, 18678882.
5. Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Praticò D. 5-lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer's disease. FASEB J 2008, 22:1169-1178. 2698428, 17998412.
6. Diamant Z, Timmers MC, van der Veen H, Friedman BS, De Smet M, Depré M, Hilliard D, Bel EH, Sterk PJ. The effect of MK-591, a novel 5-lipoxygenase-activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995, 95:42-51. 10.1016/S0091-6749(95)70151-6, 7822663.
7. Praticò D, Uryu K, Leight S, Trojanowski J, Lee V. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer's disease. J Neurosci 2001, 21(12):4183-4187.
8. Yang H, Zhuo J, Chu J, Chinnici C, Praticò D. Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase. Biol Psych 2010, 68(10):922-929.
9. Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Praticò D. Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice. Mol Neurodegener 2012, 7:1. 10.1186/1750-1326-7-1, 3277480, 22222029.
10. Chu J, Praticò D. 5-lipoxygenase as an endogenous modulator of amyloid beta formation in vivo. Ann Neurol 2011, 69:34-46. 10.1002/ana.22234, 3051361, 21280074.
11. Kenneth JL, Thomas DS. Analysis of relative gene expression data using real time quantitative PCR and the 2-ΔΔCt method. Methods 2002, 25:402-408.
12. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Hsiao Ashe K, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001, 21(2):372-381.
13. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sunh X, Frosch MP, Selkoe DJ. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003, 40:1087-1093. 10.1016/S0896-6273(03)00787-6, 14687544.
14. Guenette SY. Mechanisms of Abeta clearance and catabolism. Neuromolecular Med 2003, 4:147-160. 10.1385/NMM:4:3:147, 14716023.
15. Yao Y, Chinnici C, Tang H, Trojanowski J, Lee V, Praticò D. Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J Neuroinflammation 2004, 1:21. 10.1186/1742-2094-1-21, 527877, 15500684.
16. Miller DK, Gillard JW, Vickers PJ, Sadowski S, Léveillé C, Mancini JA, Charleson P, Dixon RA, Ford-Hutchinson AW, Fortin R. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990, 343:278-281. 10.1038/343278a0, 2300172.
17. Dixon RAF, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, Gillard JW, Miller DK. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990, 343:282-284. 10.1038/343282a0, 2300173.
18. Evans JF, Lévillé C, Mancini JA, Prasit P, Thérien M, Zamboni R, Gauthier JY, Fortin R, Charleson P, MacIntyre DE, Luell S, Bach TJ, Meurer R, Guay J, Vickers PJ, Rouzer CA, Gillard JW, Miller DK. 5-lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol Pharmacol 1991, 40:22-27.
19. Chu J, Pratico D. Pharmacological blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model. Am J Pathol 2011, 178(4):1762-1769. 10.1016/j.ajpath.2010.12.032, 3078454, 21435457.
20. Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, Spencer RH, Chu L, Ujjainwalla F, Cunningham BR, Evans JF, Becker JW. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 2007, 317:510-512. 10.1126/science.1144346, 17600184.
21. Luo WJ, Wang H, Li H, Kim BS, Shah S, Lee HJ, Thinakaran G, Kim TW, Yu G, Xu H. PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. J Biol Chem 2003, 278:7850-7854. 10.1074/jbc.C200648200, 12522139.
22. Wang R, Zhang YW, Sun P, Liu R, Zhang X, Zhang X, Xia K, Xia J, Xu H, Zhang Z. Transcriptional regulation of Pen-2, a key component of the γ-secretase complex, by CREB. Mol Cell Biol 2006, 26:1347-1354. 10.1128/MCB.26.4.1347-1354.2006, 1367199, 16449647.
23. Chu J, Zhuo JM, Pratico D. Transcriptional regulation of β-secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments. Ann Neurol 2012, 71(1):57-67. 10.1002/ana.22625, 22275252.
24. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356. 10.1126/science.1072994, 12130773.
25. Wolfe MS. Inhibition and modulation of γ-secretase for Alzheimer's disease. Neurotherapeutics 2008, 5:391-398. 10.1016/j.nurt.2008.05.010, 2572079, 18625450.
26. Geling A, Steiner H, Willem M, Bally-Cuif L, Haas C. A γ-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep 2002, 3:688-694. 10.1093/embo-reports/kvf124, 1084181, 12101103.
27. Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, Gao H, Higgins MA, May PC, Ryan TP. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor. J Biol Chem 2003, 278:46107-46116. 10.1074/jbc.M307757200, 12949072.